Purchase Order 75N91018P00317

<p>The National Cancer Institute awarded a purchase order to Epitomics Inc. for monoclonal antibody production and purification on May 8, 2014, with a ceiling value of $6,455.20. Work is performed in Hillsborough, California. The order is firm fixed price with an ultimate completion date of August 5, 2014.</p>

<p>The National Cancer Institute awarded a purchase order to Epitomics Inc. valued at $6,652.06 on August 29, 2016. Performance occurs at the awardee's Bethesda, Maryland facility. The order is priced on a firm fixed price basis with an ultimate completion date of September 29, 2016. No set-aside category was applied.</p>

<p>The National Cancer Institute awarded a purchase order to Epitomics Inc. for rabbit polyclonal antibody immunization services valued at $24,713.80, effective January 1, 2014. Work is performed in Hillsborough, California. The order covers immunization of two rabbits using standard protocols—five injections for peptides or four injections for proteins—with two test bleeds per rabbit. The order is firm fixed price with an ultimate completion date of November 28, 2014.</p>

<p>The National Cancer Institute issued a purchase order to Epitomics Inc. for $35,865.00 on September 26, 2016, for production of blocking rabbit monoclonal antibody against human CD97. Work will be performed in Cambridge, Massachusetts. The order is firm fixed price with an ultimate completion date of September 25, 2017. No set-aside was used.</p>

<p>The National Cancer Institute awarded a purchase order to Biolegend, Inc. for $22,895 in antibodies for clinical samples on May 21, 2019, with completion scheduled for July 21, 2019. Work is performed in San Diego, California. The order is priced on a firm fixed price basis with no set-aside category applied.</p>

<p>The National Cancer Institute awarded a purchase order to 10X Genomics, Inc. for $5,850.00 on March 6, 2018, for a maintenance agreement, with completion by April 4, 2018. Performance occurs in Pleasanton, California. The order is a firm fixed price acquisition with no set-aside applied.</p>

<p>The National Cancer Institute issued a purchase order to 10X Genomics, Inc. valued at $5,850.00 on February 22, 2018, for laboratory supplies. Performance takes place in Pleasanton, California, with an ultimate completion date of March 23, 2018. This is a firm fixed-price purchase order with no set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Biolegend, Inc. for $17,215.50 on August 20, 2019, for antibodies for clinical samples. Work is performed in San Diego, California, with an ultimate completion date of October 17, 2019. The order carries firm fixed price terms with no set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to 10X Genomics, Inc. for $5,850.00 on March 15, 2018, with ultimate completion on April 13, 2018. The order covers laboratory supplies under firm fixed price terms. Place of performance is Pleasanton, California.</p>

<p>The National Cancer Institute awarded a purchase order to 10X Genomics, Inc. for $7,849.00 in bio products on December 12, 2017, with an ultimate completion date of January 12, 2018. Work is performed in Pleasanton, California. The order is firm fixed price with no set-aside applied.</p>